Oncolytics announces positive preclinical data for pelareorep combination
The company said pelareorep activity was maintained when combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. The source cites an original SEC filing and describes the results as preclinical.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.